-- SK Biopharmaceuticals (KRX:326030) posted first-quarter net income attributable to shareholders of 105.2 billion won, up 351% from 23.3 billion won a year earlier, according to a Thursday filing with the Korea Exchange.
The South Korean biopharmaceutical firm's sales rose 58% year over year to 227.9 billion won from 144.4 billion won.
Shares of SK Biopharmaceuticals rose more than 2% in recent trade.